Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus imatinib with reduced-intensity chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
jRCT2031210230Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Ponatinib plus reduced-intensity chemotherapy with Imatinib plus reduced-intensity chemotherapy (2 arms). Primary endpoint: MRD-negative complete remission at end of induction. Started Oct 2018; status: active, not recruiting.
02
Drugs
ponatinibimatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031210230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210230.